GE HealthCare Technologies (GEHC) is a favored pick among institutional investors with an ownership of 77-81%. There have been significant share acquisitions and sales by notable firms such as UBS AM, PDT Partners, The Manufacturers Life Insurance, and Fora Capital. The launch of the Pristina Via System, a new mammography system, and other technological advancements like the AI Innovation Lab may boost GEHC’s stock. GEHC recently commenced secondary offerings of 13.2M and 15M shares and priced another at 10M shares. Despite some internal sales, analysts continue to view it as undervalued, making it an attractive investment. It has met the Q3 earnings estimates and given optimistic earnings guidance for FY24. Strategic partnerships are also being entered into, such as collaborating with AMN for easing tech shortage. GEHC continues to innovate with devices like the OEC 3D C-arm. CEO's sale of $309k in stocks and a secondary offering in debt exchange point to some financial strategies. However, the company remains positive about its growth indicators and has voiced ambitious growth targets until 2028.
Ge Healthcare Technologies GEHC News Analytics from Thu, 27 Jun 2024 07:00:00 GMT to Sat, 30 Nov 2024 19:46:55 GMT - Rating 8 - Innovation 9 - Information 6 - Rumor -6
